

Enzymatic transformation of vina-ginsenoside R₇ to rare notoginsenoside ST-4 using a new recombinant glycoside hydrolase from *Herpetosiphon aurantiacus*

Ru-Feng Wang · Ming-Min Zheng · Yue-De Cao · Hao Li · Chun-Xiu Li · Jian-He Xu · Zheng-Tao Wang

Received: 12 September 2014 / Revised: 26 January 2015 / Accepted: 29 January 2015
© Springer-Verlag Berlin Heidelberg 2015

Abstract An eco-friendly and convenient preparation method for notoginsenoside ST-4 has been established by completely transforming vina-ginsenoside R₇ using a recombinant glycosidase hydrolyzing enzyme (*HaGH03*) from *Herpetosiphon aurantiacus*. This enzyme specifically hydrolyzed the glucose at the C-20 position but not the external xylose or two inner glucoses at position C-3. Protein sequence BLAST revealed that *HaGH03*, composed of 749 amino acids and presumptively listed as a member of the family 3 glycoside hydrolases, has highest identity (48 %) identity with a thermostable β -glucosidase B, which was not known of any

functions for ginsenoside transformation. The steady state kinetic parameters for purified *HaGH03* measured against p-nitrophenyl β -D-glucopyranoside and vina-ginsenoside R₇ were $K_M=5.67\pm0.24$ μ M and 0.59 ± 0.23 mM, and $k_{cat}=69.2\pm0.31$ /s and 2.15 ± 0.46 /min, respectively. *HaGH03* converted 2.5 mg/mL of vina-ginsenoside R₇ to ST-4 with a molar yield of 100 % and a space-time yield of 104 mg/L/h in optimized conditions. These results underscore that *HaGH03* has much potential for the effective preparation of target ginsenosides possessing valuable pharmacological activities. This is the first report identifying an enzyme that has the ability to transform vina-ginsenoside R₇ and provides an approach to preparing rare notoginsenoside ST-4.

Electronic supplementary material The online version of this article (doi:10.1007/s00253-015-6446-z) contains supplementary material, which is available to authorized users.

R.-F. Wang · Z.-T. Wang (✉)
Department of Pharmacognosy, China Pharmaceutical University,
Nanjing 210038, People's Republic of China
e-mail: ztwang@shutcm.edu.cn

R.-F. Wang · Z.-T. Wang
The MOE Key Laboratory for Standardization of Chinese Medicines
and the SATCM Key Laboratory for New Resources and Quality
Evaluation of Chinese Medicines, Institute of Chinese Materia
Medica, Shanghai University of Traditional Chinese Medicine,
Shanghai 201203, People's Republic of China

R.-F. Wang · M.-M. Zheng · Y.-D. Cao · H. Li · C.-X. Li ·
J.-H. Xu (✉)
State Key Laboratory of Bioreactor Engineering, East China
University of Science and Technology, Shanghai 200237, People's
Republic of China
e-mail: jianhexu@ecust.edu.cn


J.-H. Xu
Shanghai Collaborative Innovation Center for Biomanufacturing
Technology, East China University of Science and Technology,
Shanghai 200237, People's Republic of China

Keywords Biotransformation · Notoginsenoside ST-4 ·
Vina-ginsenoside R₇ · Family 3 glycoside hydrolase ·
Herpetosiphon aurantiacus · Heterologous expression

Introduction

Ginsenosides are a group of dammarane-type triterpenoid saponins mainly found in plants of the genus *Panax* (Araliaceae family), such as *Panax ginseng*, *Panax quinquefolium*, *Panax notoginseng*, and *Panax vietnamensis*. Ginsenosides show a wide spectrum of pharmacological activities, including in antihypertension, cardioprotection, immunomodulation, and as an antiatherosclerotic (Attele et al. 1999; Ng 2006; Lee and Kim 2014). Ginsenosides are categorized into two major classes according to the aglycone position, shown in Fig. 1, namely protopanaxadiols (PPDs) with sugar moieties attached to positions C-3 and/or C-20, and protopanaxatriols (PPTs)

Fig. 1 Chemical structures of ginsenosides with PPD (Nos. 1–11) and PPT types (Nos. 12–19). *Glc*, β -D-glucopyranosyl; *Xyl*, β -D-xylopyranosyl; *Rha*, α -L-rhamnopyranosyl; *Ara(p)*, α -L-arabinopyranosyl; and *Ara(f)*, α -L-arabinofuranosyl. Values represent the mean of three replicates $\pm$ standard deviation



No.	Name	R ₁	R ₂	R ₃
1	Ginsenoside F ₂	-Glc	-H	-Glc
2	Ginsenoside Rb ₁	-Glc ²⁻¹ Glc	-H	-Glc ⁶⁻¹ Glc
3	Ginsenoside Rb ₂	-Glc ²⁻¹ Glc	-H	-Glc ⁶⁻¹ Ara(p)
4	Ginsenoside Rc	-Glc ²⁻¹ Glc	-H	-Glc ⁶⁻¹ Ara(f)
5	Ginsenoside Rd	-Glc ²⁻¹ Glc	-H	-Glc
6	Ginsenoside Rg ₃	-Glc ²⁻¹ Glc	-H	-H
7	Ginsenoside Rh ₂	-Glc	-H	-H
8	Notoginsenoside Fe	-Glc	-H	-Glc ⁶⁻¹ Ara(f)
9	Notoginsenoside ST-4	-Glc ²⁻¹ Glc ²⁻¹ Xyl	-H	-H
10	Notoginsenoside Fd	-Glc	-H	-Glc ⁶⁻¹ Xyl
11	Vina-ginsenoside R ₇	-Glc ²⁻¹ Glc ²⁻¹ Xyl	-H	-Glc
12	Ginsenoside Re	-H	-O-Glc ²⁻¹ Rha	-Glc
13	Ginsenoside Rg ₁	-H	-O-Glc	-Glc
14	Notoginsenoside R ₁	-H	-O-Glc ²⁻¹ Xyl	-Glc
15	Notoginsenoside R ₂	-H	-O-Glc ²⁻¹ Xyl	-H
16	Ginsenoside Rf	-H	-O-Glc ²⁻¹ Glc	-H
17	Ginsenoside Rg ₂	-H	-O-Glc ²⁻¹ Rha	-H
18	Ginsenoside Rh ₁	-H	-O-Glc	-H
19	Ginsenoside F ₁	-H	-OH	-Glc

with attachment at C-3 and/or C-6, and/or at C-20 (Wang et al. 2006; Dan et al. 2008; Liu 2012).

Recently, rare deglycosylated ginsenosides have attracted much attention owing to more potent physiological activities in vivo and favorable physical and/or chemical properties in terms of crossing cell membranes

(Tawab et al. 2003). However, the rare ginsenoside content is extremely low or undetectable in raw plant materials, which imposes restrictions on their availability and exploitation of their novelty and pharmacological activities. During the past few decades, great efforts have been made in accomplishing large-scale

preparation of rare ginsenosides by means of chemical hydrolysis, heating, and microbial/enzymatic conversion, in attempts to discover new compounds and potential drug candidates. In terms of specificity and high productivity, microbial or enzymatic methods have proved most effective and provided insight into obtaining desirable ginsenosides and other valuable chemicals of natural origin by selective cleavage of specific sugar moieties (Su et al. 2006, 2009; Chang et al. 2009; Ye et al. 2010; Park et al. 2010; Groussin and Antoniotti 2012; Jin et al. 2013; Liu et al. 2014). Many ginsenoside-hydrolyzing enzymes, mainly belonging to the glycoside hydrolase family (EC 3.2.1.-), have been identified, expressed, and applied to the transformation of predominant ginsenosides into rare ones. Recombinant ginsenoside-hydrolyzing enzymes are briefly summarized in Table 1 and are most frequently used to transform Rg₁, Rg₂, Rg₃, Re, Rc, Rb₁, Rb₂, Rd, Rf, and R₁.

Notoginsenoside ST-4, a promising agent against herpes simplex viral infection, was isolated from steam-treated notoginseng with a yield of just 0.00066 % (Pei et al. 2011). No other pharmacological activities of this rare notoginsenoside have been investigated yet because of the extremely cumbersome preparation process and the trace yield. In our previous work, notoginsenoside Ft₁, the C-20 isomer of ST-4, was shown to have activities in enhancing platelet aggregation (Gao et al. 2014a), promoting angiogenesis (Shen et al. 2012), activating both glucocorticoid and estrogen receptors (Shen et al. 2014), and having a pro-apoptotic effect on human neuroblastoma SH-SY5Y cells (Gao et al. 2014b). It should therefore be of interest to determine the biological effects of ST-4 and elucidate the structure-activity relationships of both ST-4 and Ft₁. However, there is no convenient approach to prepare notoginsenoside ST-4 on a batch scale. Of the reported ginsenosides, *vina*-ginsenoside R₇ is undoubtedly the best choice as a substrate for biotransformation into the target compound ST-4. First, *vina*-ginsenoside R₇ was identified as being of relatively high content in Vietnam ginseng and notoginseng (Minh et al. 1994; Wang et al. 2008). Second, and more importantly, it has a similar structure to notoginsenoside ST-4, except for a glucose substituted at the C-20 position. To the best of our knowledge, neither enzymes nor microorganisms have been investigated for the biotransformation of *vina*-ginsenoside R₇ into notoginsenoside ST-4. Consequently, in this work, an eco-friendly and convenient preparation method for this conversion has been established using a recombinant, newly identified ginsenosidase from *Herpetosiphon aurantiacus*. Detailed enzymatic properties of this ginsenosidase were characterized to establish its substrate specificity and the substrate spectrum.

Table 1 Ginsenosides conversion by recombinant glycoside hydrolases from family 3

No.	Microorganism	Biotransformation pathways	Reaction conditions	References
1	<i>Sanguibacter keddiei</i>	Rb ₁ →Gyp XVII→Gyp LXXV→C-K, Rb ₂ →C-O→C-Y, Rc→C-Mc 1→C-Mc, Rd→F ₂ →C-K, Rg ₃ →Rh ₂ →PPD	pH 8.0, 25 °C	Kim et al. (2012)
2	<i>Flavobacterium johnsoniae</i>	Rb ₁ →Rd→Rg ₃	pH 6.0, 37 °C	Kim et al. (2013)
3	<i>Microbacterium esteraromaticum</i>	Rb ₁ →Rd→Rg ₃	pH 7.0, 37 °C	Quan et al. (2012)
4	<i>Penicillium aculeatum</i>	Rb ₁ →Rd→F ₂ →C-K, Rb ₂ →C-O→C-Y, Rc→Mc ₁ →Mc, Rg ₃ →Rh ₂ →PPD, Rg ₁ →F ₁ , Rf→Rh ₁ →PPT	pH 4.5, 70 °C	Lee et al. (2013)
5	<i>Terrabacter ginsenosidimutans</i>	Rb ₁ →Gyp XVII, Gyp LXXV→C-K	pH 7.0, 37 °C	An et al. (2010)
6	<i>Actinosynnema mirum</i>	Rb ₂ →C-O→C-Y, Rc→Mc ₁ →C-Mc, Rd→F ₂ →Rh ₂ →PPD, Rg ₃ →Rh ₂ →PPD, Re→Rg ₂ , Rg ₁ →Rh ₁ →PPT	pH 7.0, 37 °C	Cui et al. (2013a)
7	<i>Dictyoglomus turgidum</i>	R ₁ →R ₂ →Rh ₁ →PPT, Rf→Rh ₁ →PPT, Rg ₁ →Rh ₁ →PPT	pH 6.0, 80 °C	Lee et al. (2014)
8	<i>Mucilaginibacter sp.</i>	Re→Rg ₂ , Rg ₁ →Rh ₁	pH 8.0, 30 °C	Cui et al. (2013b)
9	<i>Herpetosiphon aurantiacus</i>	<i>Vina</i> R ₇ →ST-4, Fe→Mc, NG-Fd→Mx, Re→Rg ₂ , Rg ₁ →Rh ₁ →PPT, Rc→C-Mc Rf→Rh ₁ →PPT, Rb ₂ →C-Y, R ₁ →R ₂	pH 6.5, 37 °C	This study

Materials and methods

Chemicals and materials

Vina-ginsenoside R₇, notoginsenoside ST-4, and other ginsenoside standards were supplied by the Shanghai R&D Centre for Standardization of Traditional Chinese Medicine

(Shanghai, China). Methanol and acetonitrile of HPLC grade were obtained from Fisher Scientific Co. (Santa Clara, CA, USA). *p*-Nitrophenyl (*p*NP), β -D-glucopyranoside, and *o*NP- β -D-galactopyranoside were purchased from Sigma (St. Louis, MO, USA). Deionized water was prepared by the Milli-Q system (Millipore, Bedford, MA, USA). All other chemicals and reagents were of analytical grade or better.

Molecular cloning, expression, and purification

H. aurantiacus DSM 785 (DSMZ, Braunschweig, Germany), *Escherichia coli* DH5 α , and *E. coli* BL21 (DE3) were used as the source of the β -glycosidase gene, the host for gene cloning, and the host for recombinant protein expression, respectively. The gene encoding the ginsenoside hydrolase (2250 bp) was amplified by polymerase chain reaction (PCR) using the following primers with *Bam*HI and *Hind*III restriction sites (in italics): forward 5'-CGCGGATCCATGACCGGAGCGATCAAC-3' and reverse 5'-CCCAGC TTCTAGCCCTGATTGACCTTGGC-3'. The amplified DNA fragment was purified, digested with appropriate restriction enzymes, and ligated into the expression vector pET-28a (Novagen).

E. coli BL21 (DE3) strains harboring the expression plasmid were grown in LB medium containing kanamycin (50 μ g/mL) at 37 °C to an absorbance at 600 nm (OD₆₀₀) of 0.4. Expression was induced with isopropyl- β -D-thiogalactopyranoside (IPTG) at a final concentration of 0.2 mM for 20 h at 16 °C, before centrifugation (12,000 $\times$ g at 4 °C for 10 min). Harvested cells were washed two times using 0.9 % (w/v) sodium chloride, suspended in 20 mM sodium phosphate buffer (pH 7.4, 500 mM NaCl, 20 mM imidazole), and disrupted by ultrasonication. Cell debris was removed two times by centrifugation (15,000 $\times$ g at 4 °C for 25 min). Purification of the N-terminal His-tagged fusion protein was executed using a His trap Ni-NTA FF column (GE Healthcare), which was eluted with a gradient of imidazole from 20 to 500 mM. The protein homogeneity was confirmed by 12 % sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

Enzymatic activities and properties of *H. aurantiacus* family 3 ginsenoside-hydrolyzing enzyme (*HaGH03*)

Specific activity of the purified *HaGH03* was measured at 37 °C in a 100- μ L reaction mixture containing 1.5 mg/mL of ginsenoside, or in a 500- μ L mixture with 2 mM aryl-glycoside, as well as a certain amount of *HaGH03* and 50 mM sodium phosphate buffer (pH 6.5). The hydrolysis of aryl-glycoside was terminated after 5 min by the addition of 500 μ L 1 mM Na₂CO₃, and the amount of liberated chromogenic *p*-nitrophenol (*p*NP) or *o*-nitrophenol (*o*NP) was immediately determined by the optical absorbance at 405 nm

(Larsbrink et al. 2014). One unit (U) of β -glycosidase activity was defined as the amount of protein required to produce 1 μ mol of *p*NP (*o*NP), produce 1 μ mol notoginsenoside ST-4 from *vina*-ginsenoside R₇, or decrease 1 μ mol of other ginsenosides per minute, in the given conditions. The effect of pH on the activity of *HaGH03* was investigated at 37 °C using 1.35 mM of *vina*-ginsenoside R₇ in the following buffers: sodium acetate (pH 5.0), sodium phosphate (pH 6.0–8.0), and glycine-sodium hydroxide (pH 9.0). The pH stability of *HaGH03* was assayed by analyzing its residual activity after incubation in each buffer for 12 h at 4 °C. The thermostability of *HaGH03* was investigated by determining the residual activity after incubation of the enzyme (5 mg/mL) in 50 mM sodium phosphate buffer for 1 h at various temperatures. Purified *HaGH03* was incubated with metal ions and chemical reagents at a final concentration of 1 or 10 mM for 1 h at 30 °C. The activity without reagents or metal ions was used as the control with relative activity defined as 100 %. Kinetic parameters were determined with *vina*-ginsenoside R₇ and *p*NPG in different concentrations at pH 6.5 and 40 °C.

Biotransformation of *vina*-ginsenoside R₇ and ginsenosides by *HaGH03*

Briefly, catalyzed reactions were initiated by mixing different concentrations (2.5–5.5 mg/mL) of *vina*-ginsenoside R₇ and 0.6 mg/mL *HaGH03* in 200 μ L of 50 mM sodium phosphate buffer (pH 6.5). Samples were withdrawn periodically to determine the amount of conversion and were analyzed quantitatively by ultra-high performance liquid chromatography–mass spectrometry (UHPLC-MS). The reactions were quenched with methanol to precipitate the protein. After vortexing for 30 s, the resulting mixture was centrifuged at 20,000 $\times$ g for 20 min. The supernatant was diluted by methanol with digoxin as an inner standard (IS).

To prepare notoginsenoside ST4 produced by *HaGH03*, biocatalytic resolution of 0.7 mg/mL *vina*-ginsenoside R₇ was conducted with a catalyst loading of 1.2 g of lyophilized cell-free extract in 300 mL of pH 6.5 sodium phosphate buffer for 24 h at 37 °C. For preparation of ST-4, the reaction solution was extracted two times with 100 mL of *n*-butanol. The resultant *n*-butanol layer was then combined and concentrated in a rotary evaporator at 55 °C.

Analysis method

Quantitative analysis was performed using an Agilent 1290 series UHPLC (Agilent Technologies, Waldbronn, Germany) and an Agilent 6410 Triple Quadrupole mass spectrometer equipped with an electrospray ionization source (ESI). Chromatographic separation was achieved on an ACQUITY UPLC HSS T3 column (100 mm $\times$ 2.1 mm i.d., 1.8 μ m; Waters Co., Milford, MA, USA) at 45 °C using a mobile

phase of 0.1 % formic acid with 5 mM ammonium acetate (A) and acetonitrile (B) at a flow rate of 0.4 mL/min. The gradient elution (B) steps applied to determine R₇, Fe, Rg₃, Fd, Rb₁, Rb₂, Rb₃, Rc, and XVII were set as follows: 0–1 min (15–37 %), 1–2 min (37 %), 2–2.5 min (37–40 %), 2.5–3 min (40–45 %), 3–5 min (45–80 %), and 5–6 min (90 %). The gradient elution (B) steps applied to measure R₁, Rg₁, Rg₂, F₁, Rh₁, and Re were set as follows: 0–2 min (15–29 %), 2–2.5 min (29–32 %), 2.5–4 min (32–34 %), 4–6 min (34–70 %), 6–6.5 min (70–90 %), 6.5–7.5 min (90–95 %), and 7.5–8.5 min (15 %). Mass spectrometric analysis was performed in the negative ion multiple reaction monitoring (MRM) mode with 3.4-kV capillary voltage for all experiments. The *m/z* of precursor/product ions, fragment electric (FE) voltages, and collision energies (CEs) are summarized in Table 2. NMR spectra were obtained on a Bruker AV 400 NMR spectrometer (Faellanden, Switzerland) in C₅D₅N at 25 °C.

Sequence analysis of *HaGH03*

Database searching used BLAST of Uniprot and published papers on ginsenoside-hydrolyzing enzymes belonging to the GH3 family. Detailed sequence alignment analyses were conducted using ENDscript 3 (Robert and Gouet 2014) and a multiple protein sequence alignment website (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>).

Table 2 Mass spectrometric parameters for analytes and inner standard

Analyte	Precursor/product ions	FE (V)	CE (eV)
digoxin (IS)	779.4/649.4	260	35
<i>vina</i> -ginsenoside R ₇	1077.6/945.7	205	48
notoginsenoside ST ₄	915.6/621.4	255	34
<i>Vina</i> -ginsenoside R ₇	779.4/649.4	260	35
Notoginsenoside Fe	915.6/621.4	230	36
Notoginsenoside Fd	915.6/149.2	230	50
Notoginsenoside R ₁	931.6/637.5	255	45
Ginsenoside Rb ₃	1077.9/915.6	190	45
Ginsenoside Rd	945.8/783.3	195	42
Ginsenoside Re	945.5/637.6	210	42
Ginsenoside Rf	799.5/475.5	255	45
Ginsenoside Rg ₃	783.6/621.5	210	35
Ginsenoside Rh ₁	637.5/475.5	260	25
Gypenoside XVII	945.6/179.0	250	18
Ginsenoside F ₁	637.5/475.5	250	20
Ginsenoside Rb ₂	1077.7/149.1	225	52
Ginsenoside Rc	1077.7/915.5	220	45
Ginsenoside Rg ₁	799.3/637.4	260	24
Ginsenoside Rb ₁	1107.6/945.5	235	50
Ginsenoside Rg ₂	783.5/637.4	255	32

FE fragment electric voltages, CE collision energy

Results

Cloning, expression, and purification of recombinant glycosidase *HaGH03*

The gene from *H. aurantiacus* consisting of a 2250-bp fragment encoding a presumptive family 3 glycoside hydrolase was ligated into the pET28a vector and expressed solubly in *E. coli* BL21 (DE3) under IPTG induction. The fusion protein *HaGH03* with a His-tagged *N*-terminus was purified by Ni-NTA affinity chromatography, resulting in a single band of about 81 kDa on SDS-PAGE (Fig. 2).

Biochemical properties of the newly identified ginsenosidase *HaGH03*

The newly identified ginsenosidase *HaGH03* was subjected to detailed characterization of its biochemical properties to establish its substrate specificities, estimated by catalysis of aryl-glycosides (*p*NP β Glc, *p*NP β Gal, *p*NP β Xyl, *p*NP α Glc, *o*NP β Glc, and *o*NP β Gal) and ginsenosides (Re, Rg₁, Rg₂, Rf, Rh₁, F₁, Rb₁, Rb₂, Rc, Rd, Rg₃, *vina*-ginsenoside R₇, notoginsenoside Fd, Fe, R₁, and gypenoside XVII). Table 3 shows that the specificity of *HaGH03* for aryl-glycosides was dependent on whether they were β-(1→2) or β-(1→4) linked glucopyranosides or galactopyranosides. No activity was observed toward the α-(1→4) linked glucopyranoside. The order of specific activity toward PPD-type ginsenosides listed in




Fig. 2 SDS-PAGE analysis of recombinant *HaGH03*. Lane M, molecular weight standard; lane 1, soluble fraction of crude extract of induced recombinant BL21 (DE3); lane 2, purified recombinant *HaGH03* after His trap Ni-NTA FF column

Table 3 Specific activity of purified *HaGH03* for aryl-glycosides and ginsenosides

Substrate	Specific activity ($\mu\text{mol min}^{-1} \text{mg}^{-1}$)
<i>p</i> -Nitrophenyl β -D-glucopyranoside	52.3 $\pm$ 0.8
<i>o</i> -Nitrophenyl β -D-glucopyranoside	50.5 $\pm$ 0.5
<i>p</i> -Nitrophenyl β -D-galactopyranoside	42.7 $\pm$ 1.0
<i>o</i> -Nitrophenyl β -D-galactopyranoside	40.8 $\pm$ 0.7
<i>p</i> -Nitrophenyl β -D-xylopyranoside	0.40 $\pm$ 0.03
<i>p</i> -Nitrophenyl α -D-glucopyranoside	ND
<i>Vina</i> -ginsenoside R ₇	0.019 $\pm$ 0.001
Notoginsenoside Fe	0.34 $\pm$ 0.09
Notoginsenoside Fd	1.09 $\pm$ 0.01
Notoginsenoside R ₁	0.048 $\pm$ 0.004
Ginsenoside Rb ₃	0.021 $\pm$ 0.002
Ginsenoside Rd	0.56 $\pm$ 0.02
Ginsenoside Re	0.19 $\pm$ 0.01
Ginsenoside Rf	0.010 $\pm$ 0.001
Ginsenoside Rg ₃	0.20 $\pm$ 0.01
Ginsenoside Rh ₁	0.39 $\pm$ 0.01
Gypenoside XVII	1.12 $\pm$ 0.15
Ginsenoside F ₁	0.021 $\pm$ 0.003
Ginsenoside Rb ₂	0.004 $\pm$ 0.000
Ginsenoside Rc	0.036 $\pm$ 0.008
Ginsenoside Rg ₁	0.017 $\pm$ 0.006
Ginsenoside Rb ₁	4.44 $\pm$ 0.25
Ginsenoside Rg ₂	ND

Values represent the mean of three replicates $\pm$ standard deviation

ND not detected

Table 3 was as follows: ginsenoside Rb₁ > gypenoside XVII > notoginsenoside Fd > ginsenoside Rd > notoginsenoside Fe > ginsenoside Rg₃ > ginsenoside Rc > ginsenoside Rb₃ > *vina*-ginsenoside R₇ > ginsenoside Rb₂. No hydrolysis activity was determined for ginsenoside Rg₂, and the order toward PPT-type ginsenosides was ginsenoside Rh₁ > ginsenoside Re > ginsenoside R₁ > ginsenoside F₁ > ginsenoside Rg₁ > ginsenoside Rf. The catalytic properties of *HaGH03* were assessed to examine its potential as a candidate biocatalyst for the transformation of glycosides. The effect of pH on the hydrolytic activity of *HaGH03* was investigated using *vina*-ginsenoside R₇ and *p*NPG as substrates. The maximum activity was observed around pH 6.5 (in 50 mM sodium phosphate buffer at 37 °C) (Fig. 3a and Supplementary Fig. S1a). After incubation in different buffers for 12 h at 4 °C, the enzyme retained more than 70 % of the initial activity (pH 6.5, 37 °C) from pH 5.0 to 9.0. Maximum hydrolytic activity was observed at 50 °C using *vina*-ginsenoside R₇ and *p*NPG as substrates, while the enzyme lost about 35 % of the initial activity (pH 6.5, 37 °C) at 55 °C (Fig. 3b and Supplementary




Fig. 3 a Effect of pH on the activity and stability of *HaGH03* at 37 °C using *vina*-ginsenoside R₇ as a substrate. b Effect of temperature on the activity and stability of recombinant *HaGH03* at pH 6.5 using *vina*-ginsenoside R₇ as a substrate. Data represent the mean of three replicates; error bar represents the standard deviation

Fig. S1b). The thermal inactivation of *HaGH03* followed first-order kinetics with half-lives of 47.7, 35.1, and 1.1 h at 30, 40, and 50 °C, respectively (Supplementary Fig. S1c). Irreversible alterations of proteins may take place in the presence of metal ions or chemical reagents. Supplementary Table S1 shows that the recombinant *HaGH03* activities were inhibited slightly on the addition of Pb²⁺, Cu²⁺, or Fe²⁺ at a concentration of 10 mM, as well as by EDTA. Sodium dodecyl sulfate (SDS) had the strongest inhibition effect on *HaGH03* activity even at a relatively low concentration (1 mM). No significant activation was observed for either the metal ions or the chemical reagents tested. In terms of steady state kinetic parameters, K_M values for the purified *HaGH03* measured against *p*NPG and *vina*-ginsenoside R₇ were 5.67 $\pm$ 0.24 μ M and 0.59 $\pm$ 0.23 mM, and k_{cat} values were 69.2 $\pm$ 0.31/s and 2.15 $\pm$ 0.46/min, respectively.

Biotransformation of *vina*-ginsenoside R₇ and other ginsenosides by *HaGH03*

To detect the effect of substrate concentration on the product formation, the bioconversion of *vina*-ginsenoside R₇ by *HaGH03* was performed with varied concentrations of R₇ at




Fig. 4 The time course for notoginsenoside ST-4 production catalyzed by recombinant *HaGH03*

pH 6.5 and 37 °C. In addition, the time courses of notoginsenoside ST-4 production were monitored quantitatively by MRM mode UHPLC-ESI-MS to optimize the transformation conditions. Figure 4 shows that *HaGH03* transformed *vina*-ginsenoside R_7 at 2.5 mg/mL to notoginsenoside ST-4 with a molar conversion of 100 % and a productivity of 104 mg/L/h in the optimum conditions. However, only 80 % was converted at the maximum substrate concentration tested (5.5 mg/mL) within 36 h. For a complete transformation, it is an objective demand to lengthen the reaction time with the increase of the substrate loading, which suggested us to use a moderate substrate concentration with a reasonable dose of enzyme. Finally, approximately 0.15 g notoginsenoside ST-4 with a purity of up to 99 % was produced through biocatalysis by *HaGH03*, as monitored by UPLC-MS (Fig. 5b).

In the negative ion mode, the characteristic ion of protopanaxadiol at m/z 459.3858 [aglycone-H] $^-$ was observed in the mass spectra of ST-4. Figure 5a, c shows that the fragment m/z 915.5322 [M-H] $^-$, corresponding to the elemental formula $C_{47}H_{80}O_{17}$, was consistent with the loss of one glucose residue from the substrate (m/z 1077.5830, [M-H] $^-$) at


position C-20. The product was tentatively identified using mass spectrometry, and the absolute configuration was verified by 1H NMR and ^{13}C NMR spectroscopy (Supplementary Fig. S2); NMR data were assigned by comparison with notoginsenoside ST-4.

It was of interest to preliminarily investigate whether *HaGH03* could specifically transform other notoginsenosides and ginsenosides. Here, we sought to investigate a set of substrates including two types of ginsenosides and identify the products using UPLC-Q/TOF-MS (Supplementary Fig. S3). In our experimental conditions, *HaGH03* could hydrolyze the glucose residues of F_1 and Re at the C-20 position to PPT and Rg_2 as similar as the cleaving regulation on R_7 . In addition, *HaGH03* could convert Rb_2 and Rc to ginsenoside C-Y and Mc by further cleaving the glucoses at position C-3. The enzyme also showed 100 % conversion of notoginsenosides Fe and Fd into Mc and Mx by hydrolyzing the only glucose at C-3, and it could partially hydrolyze Rf and Rg_1 to PPT via Rh_1 .

Sequence analysis of *HaGH03*

The enzymatic activity of *HaGH03* (UniprotKB accession number A9B3B2) from *H. aurantiacus* DSM 785 has not been characterized before. A protein BLAST search against the Uniprot Knowledgebase revealed that *HaGH03* has 48 % identity to a thermostable β -glucosidase B (P14002) from *Clostridium thermocellum*, which belongs to the GH3 family and does not have a known function in ginsenoside transformation. A comprehensive comparison of primary to quaternary structure prediction was conducted using multiple sequence alignment and ENDscript 3, with a GH3 from *Thermotoga neapolitana* (Q0GC07) as the template. Figure 6 shows multiple sequence alignment of *HaGH03* with enzymes of the GH3 family, including four ginsenosidases, two enzymes of known structure (Q0GC07 and D1GCC6), and two

Fig. 5 **a** Mass spectrum of notoginsenoside ST-4. **b** The UPLC-MS chromatogram of prepared notoginsenoside ST-4 by *HaGH03*. **c** Major fragmentation of sugar side chain in notoginsenoside ST-4 by Q-TOF-MS






Fig. 6 Multiple detail sequence alignment of *HaGH03* (A9B3B2) with selected GH3 enzymes by ClustalW2 and ENDscript 3, including four ginsenosidases (UniprotKB accession number: H2DGJ4, J9Y082, E7CY69, and F6C6C1), two known structures enzymes (Q0GC07 and

D1GCC6), and two characterized enzymes (P27034 and O30713). Putative catalysis active sites for nucleophiles and the acid/base (Asp233 and Glu423) were marked with red triangles (Color figure online)

characterized enzymes (P27034 and O30713), processed by ClustalW2. It has been determined through structural and functional analyses that in β -glucosidase 3B (Q0GC07) from *Thermotoga neapolitana*, domain 1 contains the nucleophile residue D242 and domain 2 has a α/β sandwich fold and contains the acid/base amino acid residue E458 (Pozzo et al. 2010). β -Glucosidases (D1GCC6 and O30713) from *Kluyveromyces marxianus* and *Agrobacterium tumefaciens* have also been analyzed and contain these conserved catalytic residues (Castle et al. 1992; Yoshida et al. 2010). *HaGH03* shares the putative active site nucleophile and the acid/base, Asp233 and Glu423, respectively, marked with red triangles in Fig. 6.

Discussion

The K_M value of *HaGH03* against *pNPG* is about 600 times lower than that of other ginsenoside-transforming enzymes belonging to glycoside hydrolase family 3, such as *bglSk* from *Sanguibacter keddii* and *bglAm* from *Actinosynnema mirum* KACC 2008^T, indicating that *HaGH03* had a better affinity to the usual substrate (Kim et al. 2012; Cui et al. 2013a). From the ratio of kinetic parameters k_{cat}/K_M (the specificity constant), *HaGH03* showed much higher activity toward *pNPG* than *vina*-ginsenoside R₇.

Theoretically, there are a lot of pathways for *vina*-ginsenoside R₇ hydrolysis by *HaGH03*, including hydrolysis of the outer or inner sugar moiety at C-3, and the glucose at C-20. This uncertainty in cleavage positions has increased the difficulty in finding appropriate enzymes with specific transformation activity to produce notoginsenoside ST-4. However, the *HaGH03*-mediated hydrolysis of *vina*-

ginsenoside R₇ only generated notoginsenoside ST-4 by cleaving the outer glucose at C-20 without affecting the outer xylose or the two inner glucoses at position C-3. In terms of specific activities toward ginsenosides (Table 3), *HaGH03* has its strongest hydrolyzing ability for ginsenoside Rb₁ among the substrates tested in our research. *HaGH03* showed similar hydrolytic activities in the transformation of Rb₁, Rb₂, and Rc as the β -glucosidase from *Dictyoglomus turgidum* (Lee et al. 2012); however, *HaGH03* exhibited a different order of hydrolytic activity toward ginsenosides, Rb₁ > Rd > Rc > Rb₂. Besides, the hydrolytic pathways of Rf₁→Rh₁→PPT, Rb₂→C-Y and Rc→C-Mc of *HaGH03* were the same as β -glucosidase from *Penicillium aculeatum*, which hydrolyzed exo-, 3-O-, and 6-O- β -glucosides but not 20-O- β -glucoside and other glycosides of ginsenosides (Lee et al. 2013). The pathway of Re→Rg₂ is identical to that of *bglAm* from *Actinosynnema mirum* KACC 20028^T, which has only 13.82 % amino acid sequence identity, through the cleavage of glucose at position C-20 (Cui et al. 2013a). In the light of our experimental data, the most parsimonious conclusion is that *HaGH03* shows a higher preference for the glucose residue at position C-20 than at position C-3. As shown in Supplementary Fig. S3, *HaGH03* does not hydrolyze other outer glycosides such as xylose or rhamnose linked to positions C-3 and C-6, or arabinopyranose or arabinofuranose linked to C-20, which is similar to the β -glucosidase from *Thermus thermophilus*. Because of the ability to cleave the glucose attached at positions C-3 and C-6, *H. aurantiacus* β -glucosidase has a wider substrate spectrum than the latter which applied to produce ginsenoside F₂ from gypenoside XVII due to the highly selective hydrolysis of the outer glucose at the C-20 position (Shin et al. 2014).

As listed in Table 1, the characterized ginsenoside-hydrolyzing enzymes exhibit promiscuous activities toward

diverse substrates, although they all belong to the glycoside hydrolase family 3. The extensive applications of less polar ginsenosides in pharmacotherapy are prompting researchers to identify enzymes that can produce minor ones by hydrolyzing major ginsenosides. With the development of biotechnology, more and more enzymes other than glucosidases, such as α -l-arabinofuranosidases and β -galactosidases cloned from microorganisms, have been used for complete conversion of major ginsenosides to rare ones (Shin et al. 2013). However, no one has investigated the transformation of *vina*-ginsenoside R₇ to notoginsenoside ST-4 before this study. The present research provides useful guidance for the promising application of HaGH03 in the enzymatic production of rare ginsenosides.

In summary, we have successfully established an eco-friendly and convenient method to obtain notoginsenoside ST-4 by completely converting *vina*-ginsenoside R₇ using a recombinant glycosidase, HaGH03, from *H. aurantiacus*. HaGH03 was overexpressed in *E. coli* BL21 (DE3) in a completely soluble form, and its detailed enzymatic properties were characterized to establish substrate specificities. The results underscore that HaGH03 has much potential for the effective preparation of various types of rare ginsenosides possessing valuable pharmacological activities, especially notoginsenoside ST-4.

Acknowledgments This work was financially supported by the National Natural Science Foundation of China (U1032604) and the Program for Changjiang Scholars and Innovative Research Team in University (IRT1071).

References

- An DS, Cui CH, Lee HG, Wang L, Kim SC, Lee ST, Jin FX, Yu HS, Chin YW, Lee HK, Im WT, Kim SG (2010) Identification and characterization of a novel *Terrabacter ginsenosidimutans* sp nov β -Glucosidase that transforms Ginsenoside Rb₁ into the rare Gypenosides XVII and LXXV. Appl Environ Microbiol 76:5827–5836
- Attele AS, Wu JA, Yuan CS (1999) Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58:1685–1693
- Castle LA, Smith KD, Morris RO (1992) Cloning and sequencing of an *Agrobacterium tumefaciens* beta-glucosidase gene involved in modifying a vir-inducing plant signal molecule. J Bacteriol 174:1478–1486
- Chang KH, Jee HS, Lee NK, Park SH, Lee NW, Paik HD (2009) Optimization of the enzymatic production of 20(S)-ginsenoside Rg₃ from white ginseng extract using response surface methodology. New Biotechnol 26:181–186
- Cui CH, Kim SC, Im WT (2013a) Characterization of the ginsenoside-transforming recombinant β -glucosidase from *Actinosynnema mirum* and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol 97:649–659
- Cui CH, Liu QM, Kim JK, Sung BH, Kim SG, Kim SC, Im WT (2013b) Identification and characterization of a *Mucilaginibacter* sp Strain QM49 β -glucosidase and its use in the production of the pharmaceutically active minor Ginsenosides (S)-Rh₁ and (S)-Rg₂. Appl Environ Microbiol 79:5788–5798
- Dan M, Su M, Gao X, Zhao T, Zhao A, Xie G, Qiu Y, Zhou M, Liu Z, Jia W (2008) Metabolite profiling of *Panax notoginseng* using UPLC–ESI-MS. Phytochemistry 69:2237–2244
- Gao B, Huang L, Liu H, Wu H, Zhang E, Yang L, Wu X, Wang Z (2014a) Platelet P2Y₁₂ receptors are involved in the haemostatic effect of notoginsenoside Ft₁, a saponin isolated from *Panax notoginseng*. Br J Pharmacol 171:214–223
- Gao B, Shi HL, Li X, Qiu SP, Wu H, Zhang BB, Wu XJ, Wang ZT (2014b) p38 MAPK and ERK1/2 pathways are involved in the pro-apoptotic effect of notoginsenoside Ft₁ on human neuroblastoma SH-SY5Y cells. Life Sci 108:63–70
- Groussin AL, Antonioti S (2012) Valuable chemicals by the enzymatic modification of molecules of natural origin: terpenoids, steroids, phenolics and related compounds. Bioresour Technol 115:237–243
- Jin S, Luo M, Wang W, Zhao CJ, Gu CB, Li CY, Zu YG, Fu YJ, Guan Y (2013) Biotransformation of polydatin to resveratrol in *Polygonum cuspidatum* roots by highly immobilized edible *Aspergillus niger* and Yeast. Bioresour Technol 136:766–770
- Kim JK, Cui CH, Yoon MH, Kim SC, Im WT (2012) Bioconversion of major ginsenosides Rg₁ to minor ginsenoside F₁ using novel recombinant ginsenoside hydrolyzing glycosidase cloned from *Sanguibacter keddiei* and enzyme characterization. J Biotechnol 161:294–301
- Kim JK, Cui CH, Liu Q, Yoon MH, Kim SC, Im WT (2013) Mass production of the ginsenoside Rg₃(S) through the combinative use of two glycoside hydrolases. Food Chem 141:1369–1377
- Larsbrink J, Rogers TE, Hemsworth GR, McKee LS, Tausin AS, Spadiut O, Klintner S, Pudlo NA, Urs K, Koropatkin NM, Creagh AL, Haynes CA, Kelly AG, Cederholm SN, Davies GJ, Martens EC, Brumer H (2014) A discrete genetic locus confers xyloglucan metabolism in select human gut Bacteroidetes. Nature 506:498–502
- Lee CH, Kim JH (2014) A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 38:161–166
- Lee GW, Kim KR, Oh DK (2012) Production of rare ginsenosides (compound Mc, compound Y and aglycon protopanaxadiol) by β -glucosidase from *Dictyoglomus turgidum* that hydrolyzes β -linked, but not α -linked, sugars in ginsenosides. Biotechnol Lett 34:1679–1686
- Lee GW, Yoo MH, Shin KC, Kim KR, Kim YS, Lee KW, Oh DK (2013) β -Glucosidase from *Penicillium aculeatum* hydrolyzes exo-, 3-O-, and 6-O- β -glucosides but not 20-O- β -glucoside and other glycosides of ginsenosides. Appl Microbiol Biotechnol 97:6601
- Lee HJ, Shin KC, Lee GW, Oh DK (2014) Production of aglycone protopanaxatriol from ginseng root extract using *Dictyoglomus turgidum* β -glucosidase that specifically hydrolyzes the xylose at the C-6 position and the glucose in protopanaxatriol-type ginsenosides. Appl Microbiol Biotechnol 98:3659–3667
- Liu ZQ (2012) Chemical insights into ginseng as a resource for natural antioxidants. Chem Rev 112:3329–3355
- Liu C, Jin Y, Yu H, Sun C, Gao P, Xiao Y, Zhang T, Xu L, Im WT, Jin F (2014) Biotransformation pathway and kinetics of the hydrolysis of the 3-O- and 20-O-multi-glucosides of PPD-type ginsenosides by ginsenosidase type I. Process Biochem 49:813–820
- Minh DN, Kasai R, Ohtani K, Ito A, Thoi Nham N, Yamasaki K, Tanaka O (1994) Saponins from *Vietnamese ginseng*, *Panax vietnamensis* Ha et Grushv. Collected in central Vietnam. II. Chem Pharm Bull 42: 115–122
- Ng TB (2006) Pharmacological activity of sanchi ginseng (*Panax notoginseng*). J Pharm Pharmacol 58:1007–1019
- Park CS, Yoo MH, Noh KH, Oh DK (2010) Biotransformation of ginsenosides by hydrolyzing the sugar moieties of ginsenosides using microbial glycosidases. Appl Microbiol Biotechnol 87:9–19

- Pei Y, Du Q, Liao PY, Chen ZP, Wang D, Yang CR, Kitazato K, Wang YF, Zhang YJ (2011) Notoginsenoside ST-4 inhibits virus penetration of herpes simplex virus in vitro. *J Asian Nat Prod Res* 13:498–504
- Pozzo T, Pasten JL, Karlsson EN, Logan DT (2010) Structural and functional analyses of β -glucosidase 3B from *Thermotoga neapolitana*: a thermostable three-domain representative of glycoside hydrolase 3. *J Mol Biol* 397:724–739
- Quan LH, Min JW, Yang DU, Kim YJ, Yang DC (2012) Enzymatic biotransformation of ginsenoside Rb₁ to 20(S)-Rg₃ by recombinant β -glucosidase from *Microbacterium esteraromaticum*. *Appl Microbiol Biotechnol* 94:377–384
- Robert X, Gouet P (2014) Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res*. doi:10.1093/nar/gku316
- Shen KK, Ji LL, Gong CY, Ma YB, Yang L, Fan Y, Hou MQ, Wang ZT (2012) Notoginsenoside Ft₁ promotes angiogenesis via HIF-1 α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. *Biochem Pharmacol* 84:784–792
- Shen KK, Leung SWS, Ji LL, Huang Y, Hou MQ, Xu AM, Wang ZT, Vanhoutte PM (2014) Notoginsenoside Ft₁ activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. *Biochem Pharmacol* 88:66–74
- Shin KC, Oh HJ, Kim BJ, Oh DK (2013) Complete conversion of major protopanaxadiol ginsenosides to compound K by the combined use of α -L-arabinofuranosidase and β -galactosidase from *Caldicellulosiruptor saccharolyticus* and β -glucosidase from *Sulfolobus acidocaldarius*. *J Biotechnol* 167:33–40
- Shin KC, Seo MJ, Oh HJ, Oh DK (2014) Highly selective hydrolysis for the outer glucose at the C-20 position in ginsenosides by β -glucosidase from *Thermus thermophilus* and its application to the production of ginsenoside F₂ from gypenoside XVII. *Biotechnol Lett* 36:1287–1293
- Su JH, Xu JH, Lu WY, Lin GQ (2006) Enzymatic transformation of ginsenoside Rg₃ to Rh₂ using newly isolated *Fusarium proliferatum* ECU2042. *J Mol Catal B Enzym* 38:113–118
- Su JH, Xu JH, Yu HL, He YC, Lu WY, Lin GQ (2009) Properties of a novel glucosidase from *Fusarium proliferatum* ECU2042 that converts ginsenoside Rg₃ into Rh₂. *J Mol Catal B Enzym* 57:278–283
- Tawab MA, Bahr U, Karas M, Wurglics M, Schubert ZM (2003) Degradation of ginsenosides in humans after oral administration. *Drug Metab Dispos* 31:1065–1071
- Wang CZ, McEntee E, Wicks S, Wu JA, Yuan CS (2006) Phytochemical and analytical studies of *Panax notoginseng* (Burk.) F.H. Chen. *J Nat Med* 60:97–106
- Wang XY, Wang D, Ma XX, Zhang YJ, Yang CR (2008) Two new dammarane-type bisdesmosides from the fruit pedicels of *Panax notoginseng*. *Helv Chim Acta* 91:60–66
- Ye L, Zhou CQ, Zhou W, Zhou P, Chen DF, Liu XH, Shi XL, Feng MQ (2010) Biotransformation of ginsenoside Rb₁ to ginsenoside Rd by highly substrate-tolerant *Paecilomyces bainier* 229-7. *Bioresour Technol* 101:7872–7876
- Yoshida E, Hidaka M, Fushinobu S, Koyanagi T, Minami H, Tamaki H, Kitaoka M, Katayama T, Kumagai H (2010) Role of a PA14 domain in determining substrate specificity of a glycoside hydrolase family 3 β -glucosidase from *Kluyveromyces marxianus*. *Biochem J* 431:39–49